Study links use of new obesity drugs to reduction of asthma exacerbations and inhaler use

New research presented at the European Congress on Obesity in Istanbul, Turkey (May 12–15) shows the use of the new GLP-1 class of obesity drugs in people with asthma is associated with a 26% fall in the number of asthma exacerbations and a 14% drop in use of asthma inhaler reliever use.